DINA PIERRE-GRAY: Open Payments
NPI 1639743131 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,131 in 79 payments from 9 companies in 2025. Trend: 2023 $354 · 2024 $2,313 · 2025 $4,131
Food & beverage: $2,851Consulting: $1,280
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $1,865 |
| Neurocrine BioSciences, Inc. | 16 | $726 |
| ABBVIE INC. | 7 | $417 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $404 |
| Teva Pharmaceuticals USA, Inc. | 9 | $244 |
| Alkermes, Inc. | 7 | $232 |
| Janssen Pharmaceuticals, Inc | 5 | $125 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
Products named: INGREZZA, COBENFY, VRAYLAR, CAPLYTA, ARISTADA, UZEDY, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across IL — which companies pay providers there.
